Madrigal Pharmaceuticals, Inc.

$83.46 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

Stock Analysis

last close $83.46
1-mo return 32.1%
3-mo return -13%
avg daily vol. 177.33T
52-week high 105.93
52-week low 52.33
market cap. $1.4B
forward pe -
annual div. -
roe -121.5%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 82.1%
baraka

Subscribe now for daily local and international financial news

Subscribe